Content Navigation
( All
None )
| Target |
Top |
| Target(s) |
HUMAN transmembrane protease serine 2 (TMPRSS2) |
Target Info
|
Inhibitor |
[1], [3] |
|
Camostat mesylate inhibits MERS-CoV, SARS-CoV and SARS-CoV-2 in vitro via inhibiting TMPRSS2 which is a serine protease that mediates the cell surface entry pathway.
|
| References |
Top |
| 1 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-280.e8.
|
| 2 |
ClinicalTrials.gov (NCT04353284) Camostat Mesylate in COVID-19 Outpatients
|
| 3 |
Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
|
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.
